<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:sbh="https://wiki.synbiohub.org/wiki/Terms/synbiohub#" xmlns:sbol="http://sbols.org/v2#" xmlns:ns0="http://www.w3.org/ns/prov#" xmlns:ns1="http://purl.org/dc/elements/1.1/" xmlns:ns2="http://purl.org/dc/terms/" xmlns:ns3="http://purl.obolibrary.org/obo/">
  <sbol:Collection rdf:about="http://examples.org/sb8b00330/1">
    <ns1:subject>unlocked</ns1:subject>
    <ns2:references>Sujatha, M. S., Sasidhar, Y. U., Balaji, P. V. Insights into the Role of the Aromatic Residue in Galactose-Binding Sites: MP2/6-311G++** Study on Galactose&#8211; and Glucose&#8211;Aromatic Residue Analogue Complexes Biochemistry 2005. 44:8554-8562.</ns2:references>
    <sbol:displayId>sb8b00330</sbol:displayId>
    <ns1:subject>GFP</ns1:subject>
    <ns1:subject>gene
delivery</ns1:subject>
    <ns2:dateSubmitted>2018-08-02</ns2:dateSubmitted>
    <ns1:subject>NEB10-&#946;</ns1:subject>
    <ns1:creator>Maria Y. Chen</ns1:creator>
    <ns1:subject>glycans</ns1:subject>
    <ns2:references>Rosell, A., Ortega-Aznar, A., Alvarez-Sabi&#769;n, J., Ferna&#769;ndez-Cadenas, I., Ribo&#769;, M., Molina, C. A., Lo, E. H., Montaner, J. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke Stroke 2006. 37:1399-1406.</ns2:references>
    <ns1:subject>cap</ns1:subject>
    <ns1:subject>glycerol</ns1:subject>
    <ns1:subject>Lectin</ns1:subject>
    <ns2:references>Samulski, R. J., Muzyczka, N. AAV-Mediated Gene Therapy for Research and Therapeutic Purposes Annu. Rev. Virol. 2014. 1:427-451.</ns2:references>
    <ns2:rightsHolder>American Chemical Society</ns2:rightsHolder>
    <ns1:subject>protease</ns1:subject>
    <ns1:subject>KasI restriction enzyme</ns1:subject>
    <sbol:version>1</sbol:version>
    <ns2:references>O&#8217;Donnell, J., Taylor, K. A., Chapman, M. S. Adeno-Associated Virus-2 and its Primary Cellular Receptor &#8211; Cryo-EM Structure of a Heparin Complex Virology 2009. 385:434-443.</ns2:references>
    <ns1:subject>DMSO</ns1:subject>
    <ns1:subject>T4 DNA ligase</ns1:subject>
    <ns1:subject>VP3</ns1:subject>
    <ns3:OBI_0001617>30614703</ns3:OBI_0001617>
    <ns1:subject>rep</ns1:subject>
    <ns1:subject>poly-l-lysine-</ns1:subject>
    <ns2:references>Robinson, T. M., Judd, J., Ho, M. L., Suh, J. Role of Tetra Amino Acid Motif Properties on the Function of Protease-Activatable Viral Vectors ACS Biomater. Sci. Eng. 2016. 2:2026-2033.</ns2:references>
    <ns1:subject>aspartic acid</ns1:subject>
    <ns2:description>Adeno-associated viruses (AAVs) are promising gene therapy vectors but may exhibit off-target delivery due to broad tissue tropism. We recently developed a synthetic protease-activatable AAV vector, named provector, that transduces cells preferentially in environments rich in matrix metalloproteinases (MMPs) which are elevated in a variety of diseases, including various cancers and heart diseases. The provector displays peptide locks made up of MMP recognition sites flanking an inactivating sequence (IS) composed of four aspartic acid residues (D4). When present, the IS prevents AAV from binding cell receptors and no transduction occurs (OFF state). High levels of MMPs cleave the recognition sequences and release the IS from the capsid surface, restoring cell receptor binding (ON state). The AAV9 provector prototype is not optimal as it displays baseline OFF transduction at 5&#8211;10% of that of the wild-type capsid, which can lead to off-target delivery. We hypothesized that changes to the IS may decrease OFF state transduction. We created a provector panel with IS of lengths 0 (D0) to 10 (D10) aspartic acid residues and characterized this panel in vitro. Notably, we find that the D10 provector has an OFF transduction of less than 1% of wild-type capsid and an ON/OFF transduction ratio of 27, the best outcome achieved for any provector thus far. In summary, our results enable us to define new design rules for the provector platform, specifically that (1) the IS is necessary for provector locking and (2) increasing the number of aspartic acid residues in this sequence improves locking.</ns2:description>
    <ns2:isPartOf>ACS Synthetic Biology</ns2:isPartOf>
    <ns1:subject>MMPs</ns1:subject>
    <ns1:subject>KasI</ns1:subject>
    <ns1:subject>D0 mutant</ns1:subject>
    <ns2:references>Bell, C. L., Gurda, B. L., Van Vliet, K., Agbandje-McKenna, M., Wilson, J. M. Identification of the Galactose Binding Domain of the Adeno-Associated Virus Serotype 9 Capsid J. Virol. 2012. 86:7326-7333.</ns2:references>
    <ns1:subject>stimulus-responsive</ns1:subject>
    <ns1:subject>adeno-associated virus</ns1:subject>
    <ns1:subject>CHO-Lec2 cells</ns1:subject>
    <ns1:subject>polyethylenimine</ns1:subject>
    <ns1:subject>provector</ns1:subject>
    <ns1:subject>Tris-HCl</ns1:subject>
    <sbol:persistentIdentity rdf:resource="http://examples.org/sb8b00330"/>
    <ns1:subject>VP1</ns1:subject>
    <ns2:dateCopyrighted>2019</ns2:dateCopyrighted>
    <ns2:references>Ren, F., Tang, R., Zhang, X., Madushi, W. M., Luo, D., Dang, Y., Li, Z., Wei, K., Chen, G. Overexpression of MMP Family Members Functions as Prognostic Biomarker for Breast Cancer Patients: A Systematic Review and Meta-Analysis PLoS One 2015. 10.</ns2:references>
    <ns2:references>Judd, J., Wei, F., Nguyen, P. Q., Tartaglia, L. J., Agbandje-McKenna, M., Silberg, J. J., Suh, J. Random Insertion of mCherry Into VP3 Domain of Adeno-associated Virus Yields Fluorescent Capsids With no Loss of Infectivity Mol. Ther.--Nucleic Acids 2012. 1.</ns2:references>
    <ns1:subject>goat</ns1:subject>
    <ns1:subject>CaCl 2</ns1:subject>
    <ns1:type>research-article</ns1:type>
    <sbol:member rdf:resource="http://examples.org/ComponentDefinition/sb8b00330_1_comp/1"/>
    <ns2:references>Elgavish, S., Shaanan, B. Lectin-carbohydrate interactions: different folds, common recognition principles Trends Biochem. Sci. 1997. 22:462-467.</ns2:references>
    <ns1:subject>MMP7</ns1:subject>
    <ns1:subject>MMP2</ns1:subject>
    <ns1:subject>Lec2</ns1:subject>
    <ns2:references>Ho, M. L., Judd, J., Kuypers, B. E., Yamagami, M., Wong, F. F., Suh, J. Efficiency of Protease-Activatable Virus Nanonodes Tuned Through Incorporation of Wild-Type Capsid Subunits Cell. Mol. Bioeng. 2014. 7:334-343.</ns2:references>
    <sbol:member rdf:resource="http://examples.org/ComponentDefinition/sb8b00330_3_comp/1"/>
    <ns1:subject>aspartic acids&#58872;forms</ns1:subject>
    <ns1:subject>MgCl 2</ns1:subject>
    <ns1:subject>polymerase</ns1:subject>
    <ns1:subject>Pluronic</ns1:subject>
    <ns2:references>Brun, M. J., Gomez, E. J., Suh, J. Stimulus-responsive viral vectors for controlled delivery of therapeutics J. Controlled Release 2017. 267:80-89.</ns2:references>
    <ns1:subject>NaCl</ns1:subject>
    <ns1:subject>benzonase</ns1:subject>
    <ns1:subject>Aromatic</ns1:subject>
    <ns2:references>Thomas, C. V., Coker, M. L., Zellner, J. L., Handy, J. R., Crumbley, A. J., Spinale, F. G. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy Circulation 1998. 97:1708-1715.</ns2:references>
    <ns1:subject>iodixanol</ns1:subject>
    <sbol:member rdf:resource="http://examples.org/Sequence/sb8b00330_6_sequence/1"/>
    <ns1:subject>capsid proteins</ns1:subject>
    <ns1:subject>Tris</ns1:subject>
    <ns1:subject>tetra-aspartic acid</ns1:subject>
    <ns1:subject>competent</ns1:subject>
    <ns2:references>Spinale, F. G. Matrix Metalloproteinases: Regulation and Dysregulation in the Failing Heart Circ. Res. 2002. 90:520-530.</ns2:references>
    <ns2:abstract>Adeno-associated viruses (AAVs) are promising gene therapy vectors but may exhibit off-target delivery due to broad tissue tropism. We recently developed a synthetic protease-activatable AAV vector, named provector, that transduces cells preferentially in environments rich in matrix metalloproteinases (MMPs) which are elevated in a variety of diseases, including various cancers and heart diseases. The provector displays peptide locks made up of MMP recognition sites flanking an inactivating sequence (IS) composed of four aspartic acid residues (D4). When present, the IS prevents AAV from binding cell receptors and no transduction occurs (OFF state). High levels of MMPs cleave the recognition sequences and release the IS from the capsid surface, restoring cell receptor binding (ON state). The AAV9 provector prototype is not optimal as it displays baseline OFF transduction at 5&#8211;10% of that of the wild-type capsid, which can lead to off-target delivery. We hypothesized that changes to the IS may decrease OFF state transduction. We created a provector panel with IS of lengths 0 (D0) to 10 (D10) aspartic acid residues and characterized this panel in vitro. Notably, we find that the D10 provector has an OFF transduction of less than 1% of wild-type capsid and an ON/OFF transduction ratio of 27, the best outcome achieved for any provector thus far. In summary, our results enable us to define new design rules for the provector platform, specifically that (1) the IS is necessary for provector locking and (2) increasing the number of aspartic acid residues in this sequence improves locking.</ns2:abstract>
    <ns1:subject>aspartic acid residues</ns1:subject>
    <ns1:subject>locked</ns1:subject>
    <ns1:creator>Tawana M. Robinson</ns1:creator>
    <ns2:references>Shen, S., Bryant, K. D., Brown, S. M., Randell, S. H., Asokan, A. Terminal N-Linked Galactose Is the Primary Receptor for Adeno-associated Virus 9 J. Biol. Chem. 2011. 286:13532-13540.</ns2:references>
    <ns2:type rdf:resource="http://purl.org/dc/dcmitype/Text"/>
    <ns1:subject>glycine</ns1:subject>
    <sbol:member rdf:resource="http://examples.org/Sequence/sb8b00330_1_sequence/1"/>
    <ns2:isPartOf rdf:resource="http://pubs.acs.org/journal/asbcd6"/>
    <sbol:member rdf:resource="http://examples.org/Sequence/sb8b00330_3_sequence/1"/>
    <ns1:subject>lectin</ns1:subject>
    <ns1:subject>enzyme-responsive</ns1:subject>
    <sbol:member rdf:resource="http://examples.org/Sequence/sb8b00330_4_sequence/1"/>
    <ns1:creator>Junghae Suh</ns1:creator>
    <ns3:OBI_0002110 rdf:resource="https://doi.org/10.1021/acssynbio.8b00330"/>
    <ns2:title>Longer Inactivating Sequence in Peptide Lock Improves Performance of Synthetic Protease-Activatable Adeno-Associated Virus</ns2:title>
    <sbol:member rdf:resource="http://examples.org/Sequence/sb8b00330_5_sequence/1"/>
    <ns1:subject>MMP</ns1:subject>
    <ns2:references>Judd, J., Ho, M. L., Tiwari, A., Gomez, E. J., Dempsey, C., Van Vliet, K., Igoshin, O. A., Silberg, J. J., Agbandje-McKenna, M., Suh, J. Tunable Protease-Activatable Virus Nanonodes ACS Nano 2014. 8:4740-4746.</ns2:references>
    <ns2:references>Levy, H. C., Bowman, V. D., Govindasamy, L., McKenna, R., Nash, K., Warrington, K., Chen, W., Muzyczka, N., Yan, X., Baker, T. S., Agbandje-McKenna, M. Heparin binding induces conformational changes in Adeno-associated virus serotype 2 J. Struct. Biol. 2009. 165:146-156.</ns2:references>
    <ns1:subject>Protease</ns1:subject>
    <ns1:subject>AAV</ns1:subject>
    <ns1:subject>IgG</ns1:subject>
    <ns1:subject>ZnCl 2</ns1:subject>
    <ns1:subject>aspartic acid motif</ns1:subject>
    <ns1:subject>VP3 capsid protein</ns1:subject>
    <ns1:subject>MMP9</ns1:subject>
    <ns1:subject>Tris-Cl</ns1:subject>
    <ns1:subject>Nuclease</ns1:subject>
    <ns1:subject>nuclease</ns1:subject>
    <ns1:subject>amino acids</ns1:subject>
    <ns1:subject>galactosyl residues</ns1:subject>
    <ns1:subject>penicillin&#8211;streptomycin</ns1:subject>
    <ns1:subject>ProvIS</ns1:subject>
    <ns1:subject>VPs</ns1:subject>
    <ns1:subject>lysines</ns1:subject>
    <ns1:subject>heparan sulfate proteoglycan</ns1:subject>
    <ns1:subject>HRP</ns1:subject>
    <sbol:member rdf:resource="http://examples.org/ComponentDefinition/sb8b00330_5_comp/1"/>
    <ns1:subject>EDTA</ns1:subject>
    <sbol:member rdf:resource="http://examples.org/ComponentDefinition/sb8b00330_6_comp/1"/>
    <ns1:subject>HEK293T cells</ns1:subject>
    <ns0:wasDerivedFrom rdf:resource="https://pubs.acs.org/doi/10.1021/acssynbio.8b00330"/>
    <ns1:subject>human</ns1:subject>
    <ns2:references>Kenny, H. A., Kaur, S., Coussens, L. M., Lengyel, E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin J. Clin. Invest. 2008. 118:1367-1379.</ns2:references>
    <ns1:subject>matrix metalloproteinases</ns1:subject>
    <ns1:subject>viruses</ns1:subject>
    <sbol:member rdf:resource="http://examples.org/ComponentDefinition/sb8b00330_4_comp/1"/>
    <ns1:subject>bovine</ns1:subject>
    <ns2:references> Protease-activatable adeno-associated virus vector for gene delivery to damaged heart tissue  2019.</ns2:references>
    <ns2:references>Newby, A. C. Metalloproteinases and vulnerable atherosclerotic plaques Trends Cardiovasc. Med. 2007. 17:253-258.</ns2:references>
    <sbol:member rdf:resource="http://examples.org/ComponentDefinition/sb8b00330_2_comp/1"/>
    <ns1:subject>peptide</ns1:subject>
    <ns2:references>Ho, M. L., Adler, B. A., Torre, M. L., Silberg, J. J., Suh, J. SCHEMA Computational Design of Virus Capsid Chimeras: Calibrating How Genome Packaging, Protection, and Transduction Correlate with Calculated Structural Disruption ACS Synth. Biol. 2013. 2:724-733.</ns2:references>
    <ns1:publisher>American Chemical
Society</ns1:publisher>
    <ns1:subject>phosphate-</ns1:subject>
    <ns1:subject>BSA</ns1:subject>
    <ns1:subject>VP2</ns1:subject>
    <ns1:subject>galactose</ns1:subject>
    <sbol:member rdf:resource="http://examples.org/Sequence/sb8b00330_2_sequence/1"/>
    <ns1:subject>scGFP</ns1:subject>
    <ns1:subject>aspartic-acid-based</ns1:subject>
    <ns1:subject>aspartic acids</ns1:subject>
    <ns2:references>Evans, A. C., Thadani, N. N., Suh, J. Biocomputing nanoplatforms as therapeutics and diagnostics J. Controlled Release 2016. 240:387-393.</ns2:references>
    <ns1:subject>peptide lock</ns1:subject>
    <ns1:subject>amino acid</ns1:subject>
    <ns1:subject>VP</ns1:subject>
    <ns2:references>Cathcart, J., Pulkoski-Gross, A., Cao, J. Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas Genes Dis. 2015. 2:26-34.</ns2:references>
    <ns1:subject>synthetic
virology</ns1:subject>
    <ns1:subject>T4 polynucleotide kinase</ns1:subject>
    <ns1:subject>HSPG</ns1:subject>
  </sbol:Collection>
  <sbol:Sequence rdf:about="http://examples.org/Sequence/sb8b00330_1_sequence/1">
    <sbol:encoding rdf:resource="http://www.chem.qmul.ac.uk/iubmb/misc/naseq.html"/>
    <sbol:elements>ggaggc</sbol:elements>
    <sbol:version>1</sbol:version>
    <sbol:persistentIdentity rdf:resource="http://examples.org/Sequence/sb8b00330_1_sequence"/>
    <sbol:displayId>sb8b00330_1_sequence</sbol:displayId>
  </sbol:Sequence>
  <sbol:Sequence rdf:about="http://examples.org/Sequence/sb8b00330_4_sequence/1">
    <sbol:encoding rdf:resource="http://www.chem.qmul.ac.uk/iubmb/misc/naseq.html"/>
    <sbol:elements>cctatg</sbol:elements>
    <sbol:version>1</sbol:version>
    <sbol:displayId>sb8b00330_4_sequence</sbol:displayId>
    <sbol:persistentIdentity rdf:resource="http://examples.org/Sequence/sb8b00330_4_sequence"/>
  </sbol:Sequence>
  <sbol:Sequence rdf:about="http://examples.org/Sequence/sb8b00330_3_sequence/1">
    <sbol:elements>agtatg</sbol:elements>
    <sbol:version>1</sbol:version>
    <sbol:displayId>sb8b00330_3_sequence</sbol:displayId>
    <sbol:persistentIdentity rdf:resource="http://examples.org/Sequence/sb8b00330_3_sequence"/>
    <sbol:encoding rdf:resource="http://www.chem.qmul.ac.uk/iubmb/misc/naseq.html"/>
  </sbol:Sequence>
  <sbol:ComponentDefinition rdf:about="http://examples.org/ComponentDefinition/sb8b00330_4_comp/1">
    <sbol:version>1</sbol:version>
    <sbol:type rdf:resource="http://www.biopax.org/release/biopax-level3.owl#DnaRegion"/>
    <sbol:sequence rdf:resource="http://examples.org/Sequence/sb8b00330_4_sequence/1"/>
    <ns0:wasGeneratedBy rdf:resource="https://synbiohub.org/public/sbksactivities/ACS_Synbio_Generation/1"/>
    <ns0:wasDerivedFrom rdf:resource="https://doi.org/10.1021/acssynbio.8b00330"/>
    <sbol:displayId>sb8b00330_4_comp</sbol:displayId>
    <sbol:persistentIdentity rdf:resource="http://examples.org/ComponentDefinition/sb8b00330_4_comp"/>
    <sbh:supplementalFile rdf:resource="file:///C:/Users/JVM/Downloads/sequence_supplementals/synbict_output/sb8b00330/suppl/sb-2018-00330r_si_001.pdf"/>
  </sbol:ComponentDefinition>
  <sbol:ComponentDefinition rdf:about="http://examples.org/ComponentDefinition/sb8b00330_1_comp/1">
    <sbol:displayId>sb8b00330_1_comp</sbol:displayId>
    <ns0:wasDerivedFrom rdf:resource="https://doi.org/10.1021/acssynbio.8b00330"/>
    <sbol:persistentIdentity rdf:resource="http://examples.org/ComponentDefinition/sb8b00330_1_comp"/>
    <sbol:version>1</sbol:version>
    <sbol:type rdf:resource="http://www.biopax.org/release/biopax-level3.owl#DnaRegion"/>
    <sbol:sequence rdf:resource="http://examples.org/Sequence/sb8b00330_1_sequence/1"/>
    <sbh:supplementalFile rdf:resource="file:///C:/Users/JVM/Downloads/sequence_supplementals/synbict_output/sb8b00330/suppl/sb-2018-00330r_si_001.pdf"/>
    <ns0:wasGeneratedBy rdf:resource="https://synbiohub.org/public/sbksactivities/ACS_Synbio_Generation/1"/>
  </sbol:ComponentDefinition>
  <sbol:ComponentDefinition rdf:about="http://examples.org/ComponentDefinition/sb8b00330_5_comp/1">
    <sbh:supplementalFile rdf:resource="file:///C:/Users/JVM/Downloads/sequence_supplementals/synbict_output/sb8b00330/suppl/sb-2018-00330r_si_001.pdf"/>
    <ns0:wasGeneratedBy rdf:resource="https://synbiohub.org/public/sbksactivities/ACS_Synbio_Generation/1"/>
    <sbol:version>1</sbol:version>
    <sbol:type rdf:resource="http://www.biopax.org/release/biopax-level3.owl#DnaRegion"/>
    <ns0:wasDerivedFrom rdf:resource="https://doi.org/10.1021/acssynbio.8b00330"/>
    <sbol:persistentIdentity rdf:resource="http://examples.org/ComponentDefinition/sb8b00330_5_comp"/>
    <sbol:sequence rdf:resource="http://examples.org/Sequence/sb8b00330_5_sequence/1"/>
    <sbol:displayId>sb8b00330_5_comp</sbol:displayId>
  </sbol:ComponentDefinition>
  <sbol:Sequence rdf:about="http://examples.org/Sequence/sb8b00330_6_sequence/1">
    <sbol:encoding rdf:resource="http://www.chem.qmul.ac.uk/iubmb/misc/naseq.html"/>
    <sbol:elements>tcctct</sbol:elements>
    <sbol:persistentIdentity rdf:resource="http://examples.org/Sequence/sb8b00330_6_sequence"/>
    <sbol:displayId>sb8b00330_6_sequence</sbol:displayId>
    <sbol:version>1</sbol:version>
  </sbol:Sequence>
  <sbol:Sequence rdf:about="http://examples.org/Sequence/sb8b00330_5_sequence/1">
    <sbol:elements>cacgcc</sbol:elements>
    <sbol:displayId>sb8b00330_5_sequence</sbol:displayId>
    <sbol:persistentIdentity rdf:resource="http://examples.org/Sequence/sb8b00330_5_sequence"/>
    <sbol:encoding rdf:resource="http://www.chem.qmul.ac.uk/iubmb/misc/naseq.html"/>
    <sbol:version>1</sbol:version>
  </sbol:Sequence>
  <sbol:Sequence rdf:about="http://examples.org/Sequence/sb8b00330_2_sequence/1">
    <sbol:encoding rdf:resource="http://www.chem.qmul.ac.uk/iubmb/misc/naseq.html"/>
    <sbol:persistentIdentity rdf:resource="http://examples.org/Sequence/sb8b00330_2_sequence"/>
    <sbol:displayId>sb8b00330_2_sequence</sbol:displayId>
    <sbol:elements>agaggc</sbol:elements>
    <sbol:version>1</sbol:version>
  </sbol:Sequence>
  <sbol:ComponentDefinition rdf:about="http://examples.org/ComponentDefinition/sb8b00330_6_comp/1">
    <sbol:displayId>sb8b00330_6_comp</sbol:displayId>
    <sbol:sequence rdf:resource="http://examples.org/Sequence/sb8b00330_6_sequence/1"/>
    <ns0:wasDerivedFrom rdf:resource="https://doi.org/10.1021/acssynbio.8b00330"/>
    <sbol:version>1</sbol:version>
    <ns0:wasGeneratedBy rdf:resource="https://synbiohub.org/public/sbksactivities/ACS_Synbio_Generation/1"/>
    <sbol:type rdf:resource="http://www.biopax.org/release/biopax-level3.owl#DnaRegion"/>
    <sbh:supplementalFile rdf:resource="file:///C:/Users/JVM/Downloads/sequence_supplementals/synbict_output/sb8b00330/suppl/sb-2018-00330r_si_001.pdf"/>
    <sbol:persistentIdentity rdf:resource="http://examples.org/ComponentDefinition/sb8b00330_6_comp"/>
  </sbol:ComponentDefinition>
  <sbol:ComponentDefinition rdf:about="http://examples.org/ComponentDefinition/sb8b00330_3_comp/1">
    <sbol:sequence rdf:resource="http://examples.org/Sequence/sb8b00330_3_sequence/1"/>
    <sbh:supplementalFile rdf:resource="file:///C:/Users/JVM/Downloads/sequence_supplementals/synbict_output/sb8b00330/suppl/sb-2018-00330r_si_001.pdf"/>
    <sbol:persistentIdentity rdf:resource="http://examples.org/ComponentDefinition/sb8b00330_3_comp"/>
    <sbol:version>1</sbol:version>
    <ns0:wasGeneratedBy rdf:resource="https://synbiohub.org/public/sbksactivities/ACS_Synbio_Generation/1"/>
    <ns0:wasDerivedFrom rdf:resource="https://doi.org/10.1021/acssynbio.8b00330"/>
    <sbol:displayId>sb8b00330_3_comp</sbol:displayId>
    <sbol:type rdf:resource="http://www.biopax.org/release/biopax-level3.owl#DnaRegion"/>
  </sbol:ComponentDefinition>
  <sbol:ComponentDefinition rdf:about="http://examples.org/ComponentDefinition/sb8b00330_2_comp/1">
    <sbh:supplementalFile rdf:resource="file:///C:/Users/JVM/Downloads/sequence_supplementals/synbict_output/sb8b00330/suppl/sb-2018-00330r_si_001.pdf"/>
    <sbol:version>1</sbol:version>
    <sbol:type rdf:resource="http://www.biopax.org/release/biopax-level3.owl#DnaRegion"/>
    <ns0:wasGeneratedBy rdf:resource="https://synbiohub.org/public/sbksactivities/ACS_Synbio_Generation/1"/>
    <ns0:wasDerivedFrom rdf:resource="https://doi.org/10.1021/acssynbio.8b00330"/>
    <sbol:displayId>sb8b00330_2_comp</sbol:displayId>
    <sbol:persistentIdentity rdf:resource="http://examples.org/ComponentDefinition/sb8b00330_2_comp"/>
    <sbol:sequence rdf:resource="http://examples.org/Sequence/sb8b00330_2_sequence/1"/>
  </sbol:ComponentDefinition>
</rdf:RDF>
